Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 5275

1.

Potential effects of nicotine on glioblastoma and chemoradiotherapy: a review.

McConnell DD, Carr SB, Litofsky NS.

Expert Rev Neurother. 2019 May 16:1-11. doi: 10.1080/14737175.2019.1617701. [Epub ahead of print]

PMID:
31092064
3.

Evaluation of Glycolytic Response to Multiple Classes of Anti-glioblastoma Drugs by Noninvasive Measurement of Pyruvate Kinase M2 Using [18F]DASA-23.

Beinat C, Patel CB, Xie Y, Gambhir SS.

Mol Imaging Biol. 2019 Apr 15. doi: 10.1007/s11307-019-01353-2. [Epub ahead of print]

PMID:
30989436
4.

Chloroethylating anticancer drug-induced mutagenesis and its repair in Escherichia coli.

Yamada Y, Watanabe S, Okamoto K, Arimoto S, Takahashi E, Negishi K, Negishi T.

Genes Environ. 2019 Apr 5;41:11. doi: 10.1186/s41021-019-0123-x. eCollection 2019.

5.

A Multi-Center Retrospective Comparison of Induction Chemoimmunotherapy Regimens on Outcomes in Transplant-eligible Patients with Previously Untreated Mantle Cell Lymphoma.

Ng ZY, Bishton M, Ritchie D, Campbell R, Gilbertson M, Hill K, Ratnasingam S, Schwarer A, Manos K, Shorten S, Ng M, Nelson N, Xin L, De Mel Widanalage S, Sunny T, Purtill D, Poon M, Johnston A, Cochrane T, Lee HP, Hapgood G, Tam C, Opat S, Hawkes E, Seymour J, Cheah CY.

Hematol Oncol. 2019 Apr 15. doi: 10.1002/hon.2618. [Epub ahead of print]

PMID:
30983008
6.

Autologous Stem Cell Transplantation in Central Nervous System Lymphoma: A Multicenter Retrospective Series and a Review of the Literature.

Dholaria BR, Kumar A, Azzuqua AG, Nishihori T, Kharfan-Dabaja MA, Tun HW, Ayala E.

Clin Lymphoma Myeloma Leuk. 2019 Feb 26. pii: S2152-2650(18)31201-1. doi: 10.1016/j.clml.2019.02.013. [Epub ahead of print]

PMID:
30914301
7.

Allogeneic Transplantation after Myeloablative Rituximab/BEAM ± Bortezomib for Patients with Relapsed/Refractory Lymphoid Malignancies: 5-Year Follow-Up Results.

Chamoun K, Milton DR, Ledesma C, Young KH, Jabbour EJ, Alatrash G, Anderlini P, Bashir Q, Ciurea SO, Marin D, Molldrem JJ, Olson AL, Oran B, Popat UR, Rondon G, Champlin RE, Gulbis AM, Khouri IF.

Biol Blood Marrow Transplant. 2019 Mar 1. pii: S1083-8791(19)30147-8. doi: 10.1016/j.bbmt.2019.02.022. [Epub ahead of print]

PMID:
30826465
8.

A comprehensive analysis of factors related to carmustine/bevacizumab response in recurrent glioblastoma.

Cardona AF, Rojas L, Wills B, Ruiz-Patiño A, Abril L, Hakim F, Jiménez E, Useche N, Bermúdez S, Mejía JA, Ramón JF, Carranza H, Vargas C, Otero J, Archila P, Rodríguez J, Rodríguez J, Behaine J, González D, Jacobo J, Cifuentes H, Feo O, Penagos P, Pineda D, Ricaurte L, Pino LE, Vargas C, Marquez JC, Mantilla MI, Ortiz LD, Balaña C, Rosell R, Zatarain-Barrón ZL, Arrieta O.

Clin Transl Oncol. 2019 Feb 23. doi: 10.1007/s12094-019-02066-2. [Epub ahead of print]

PMID:
30798512
9.

Radiotherapy or Autologous Stem-Cell Transplantation for Primary CNS Lymphoma in Patients 60 Years of Age and Younger: Results of the Intergroup ANOCEF-GOELAMS Randomized Phase II PRECIS Study.

Houillier C, Taillandier L, Dureau S, Lamy T, Laadhari M, Chinot O, Moluçon-Chabrot C, Soubeyran P, Gressin R, Choquet S, Damaj G, Thyss A, Abraham J, Delwail V, Gyan E, Sanhes L, Cornillon J, Garidi R, Delmer A, Tanguy ML, Al Jijakli A, Morel P, Bourquard P, Moles MP, Chauchet A, Gastinne T, Constans JM, Langer A, Martin A, Moisson P, Lacomblez L, Martin-Duverneuil N, Delgadillo D, Turbiez I, Feuvret L, Cassoux N, Touitou V, Ricard D, Hoang-Xuan K, Soussain C; Intergroupe GOELAMS–ANOCEF and the LOC Network for CNS Lymphoma.

J Clin Oncol. 2019 Apr 1;37(10):823-833. doi: 10.1200/JCO.18.00306. Epub 2019 Feb 20.

PMID:
30785830
10.

Total Methionine Restriction Treatment of Cancer.

Hoffman RM, Kokkinakis DM, Frenkel EP.

Methods Mol Biol. 2019;1866:163-171. doi: 10.1007/978-1-4939-8796-2_13.

PMID:
30725415
11.

BEAM or BUCYVP16-conditioning regimen for autologous stem-cell transplantation in non-Hodgkin's lymphomas.

Singer S, Sharma N, Dean R, Zhao Q, Abounader D, Elder P, Hofmeister CC, Benson DM, Rosko A, Penza S, Andritsos L, Vasu S, Jaglowski S, William BM, Bolwell B, Pohlman B, Kalaycio M, Jagadeesh D, Hill B, Sobecks R, Devine SM, Majhail NS, Efebera YA.

Bone Marrow Transplant. 2019 Feb 4. doi: 10.1038/s41409-019-0463-y. [Epub ahead of print]

PMID:
30718797
12.

BEAM versus BUCYVP16 Conditioning before Autologous Hematopoietic Stem Cell Transplant in Patients with Hodgkin Lymphoma.

Singer S, Dean R, Zhao Q, Sharma N, Abounader D, Elder P, Hofmeister CC, Benson DM, Rosko A, Penza S, Andritsos L, Vasu S, Jaglowski S, William BM, Bolwell B, Pohlman B, Kalaycio M, Jagadeesh D, Hill B, Sobecks R, Devine SM, Majhail NS, Efebera YA.

Biol Blood Marrow Transplant. 2019 Feb 1. pii: S1083-8791(19)30090-4. doi: 10.1016/j.bbmt.2019.01.032. [Epub ahead of print]

PMID:
30716453
13.

Leptomeningeal Gliomatosis: A Single Institution Study of 31 Patients.

Autran D, Barrie M, Matta M, Monserrat C, Campello C, Petrirena G, Boucard C, Padovani L, Loundou A, Appay R, Graillon T, Dufour H, Figarella-Branger D, Chinot O, Tabouret E.

Anticancer Res. 2019 Feb;39(2):1035-1041. doi: 10.21873/anticanres.13210.

PMID:
30711992
14.

In situ thermo-co-electroresponsive mucogel for controlled release of bioactive agent.

Akilo OD, Kumar P, Choonara YE, du Toit LC, Pradeep P, Modi G, Pillay V.

Int J Pharm. 2019 Mar 25;559:255-270. doi: 10.1016/j.ijpharm.2019.01.044. Epub 2019 Jan 26.

PMID:
30690131
15.

Mapping the Human Kinome in Response to DNA Damage.

Owusu M, Bannauer P, Ferreira da Silva J, Mourikis TP, Jones A, Májek P, Caldera M, Wiedner M, Lardeau CH, Mueller AC, Menche J, Kubicek S, Ciccarelli FD, Loizou JI.

Cell Rep. 2019 Jan 15;26(3):555-563.e6. doi: 10.1016/j.celrep.2018.12.087.

16.

Designing Next-Generation Local Drug Delivery Vehicles for Glioblastoma Adjuvant Chemotherapy: Lessons from the Clinic.

Tabet A, Jensen MP, Parkins CC, Patil PG, Watts C, Scherman OA.

Adv Healthc Mater. 2019 Feb;8(3):e1801391. doi: 10.1002/adhm.201801391. Epub 2019 Jan 11. Review.

PMID:
30632715
17.

Rituximab in patients with primary CNS lymphoma (HOVON 105/ALLG NHL 24): a randomised, open-label, phase 3 intergroup study.

Bromberg JEC, Issa S, Bakunina K, Minnema MC, Seute T, Durian M, Cull G, Schouten HC, Stevens WBC, Zijlstra JM, Baars JW, Nijland M, Mason KD, Beeker A, van den Bent MJ, Beijert M, Gonzales M, de Jong D, Doorduijn JK.

Lancet Oncol. 2019 Feb;20(2):216-228. doi: 10.1016/S1470-2045(18)30747-2. Epub 2019 Jan 7.

PMID:
30630772
18.

Autologous transplantation as consolidation for high risk aggressive T-cell non-Hodgkin lymphoma: a SWOG 9704 intergroup trial subgroup analysis.

Al-Mansour Z, Li H, Cook JR, Constine LS, Couban S, Stewart DA, Shea TC, Porcu P, Winter JN, Kahl BS, Smith SM, Marcellus DC, Barton KP, Mills GM, LeBlanc M, Rimsza LM, Forman SJ, Leonard JP, Fisher RI, Friedberg JW, Stiff PJ.

Leuk Lymphoma. 2019 Jan 10:1-8. doi: 10.1080/10428194.2018.1563691. [Epub ahead of print]

PMID:
30628511
19.
20.

Biodegradable wafers releasing Temozolomide and Carmustine for the treatment of brain cancer.

Shapira-Furman T, Serra R, Gorelick N, Doglioli M, Tagliaferri V, Cecia A, Peters M, Kumar A, Rottenberg Y, Langer R, Brem H, Tyler B, Domb AJ.

J Control Release. 2019 Feb 10;295:93-101. doi: 10.1016/j.jconrel.2018.12.048. Epub 2018 Dec 31.

PMID:
30605703

Supplemental Content

Loading ...
Support Center